MUMBAI: Morepen Laboratories has unleashed Empamore, a wallet-friendly weapon against Type 2 diabetes, heart failure and kidney disease that promises to shake up treatment for millions in the world's diabetes capital.
With India groaning under the weight of 101 million diabetes cases, the pharmaceutical firm's latest offering aims to deliver the same therapeutic punch as pricier alternatives at a fraction of the cost—a sweet deal for patients previously priced out of optimal care.
The new drug, empagliflozin, belongs to the coveted class of SGLT2 inhibitors and will be available in various formulations, including combinations with metformin. All products are manufactured at Morepen's facilities, which boast the American regulator's stamp of approval.
"At Morepen, we are dedicated to democratising healthcare by making world-class treatments accessible to all," declared vice president of sales & marketing Ashutosh Sharma. "With Empamore, we are providing a trusted, high-quality diabetes treatment at nearly 90 per cent lower cost than existing brands, helping millions manage their condition effectively without financial strain."
This aggressive pricing strategy aims to capture a hefty slice of India's diabetes market, which is expected to grow at a robust 10.9 per cent compound annual growth rate as pre-diabetes cases swell to a staggering 136 million.
Morepen is no newcomer to the diabetes battleground. The company has already flooded the market with more than 12.33 million glucometers and a mind-boggling 1.65 billion blood glucose strips, establishing itself as a familiar name in medicine cabinets across the subcontinent.
The firm's latest offering promises more than just glycaemic control, addressing cardiovascular and renal complications while packaging the pills in perforated strips for patients who might otherwise struggle with adherence.
With a global footprint spanning 82 countries, Morepen's bargain-basement diabetes treatment may soon be sweetening the lives of patients far beyond Indian shores—proving that sometimes, the best medicine is the one you can actually afford.
